IHE ETF Implied Analyst Target Price at $94.45, Upside to Analyst Targets 10.24%

The iShares U.S. Pharmaceuticals ETF (IHE) is expected to reach $94.45 per unit based on its underlying holdings, implying 10.24% upside from the recent price of $85.67. Analysts see strong potential for Evolus Inc (EOLS), CorMedix Inc (CRMD), and Rapport Therapeutics Inc (RAPP), with potential upside of 236.22%, 157.73%, and 93.52%, respectively.